The big question on investors’ minds is what marijuana stock could be the next to move higher? While there’s no way of knowing with any certainty, one of the industry’s worst-performing stocks of late could actually turn out to be one of its best performers in the months to come. If just a single clinical trial works in favor of Cara Therapeutics (NASDAQ:CARA), it could regain everything it’s recently lost and possibly hit a $1 billion market cap.
- Dan Bilzerian: My Plans to Conquer Marijuana Industry
- Hundreds of Entrepreneurs Have Applied for Arkansas Medical Cannabis Licenses
- Marijuana Consumers Aren’t Hard-core Partiers, They Just Want to Sleep
- This Is Why Nevada Has Summoned the Gaming Policy Committee to Talk Cannabis
- Judge Dismisses Lawsuit Challenging Ban of Medical Cannabis in Kentucky
On Sept. 18, 2017, at 4:30 p.m. CT, the Natural State closed the application window for cultivators and distributors seeking Arkansas medical cannabis licenses. The Department of Finance and Administration received a total of 322 applications, with roughly 200 coming in on the last day to apply.
The ongoing drama over who can distribute recreational marijuana in the state of Nevada is now heading before the Nevada Supreme Court.
On Sept. 18, 2017, the Louisiana State University Agricultural Center announced that it had finalized its LSU medical marijuana contract with GB Sciences Louisiana, a subsidiary of GB Sciences (OTCQB:GBLX).